|Articles|June 1, 2002

Pimecrolimus goes pharmacogenetic

Previewing what may become routine in a few years, researchers have used genetic profiling to evaluate efficacy and adverse effects of a drug undergoing clinical trials for the treatment of psoriasis.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME